74. Prolactin secreting pituitary adenoma Clinical trials / Disease details
Clinical trials : 19 / Drugs : 28 - (DrugBank : 10) / Drug target genes : 14 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-007348-32-IT (EUCTR) | 07/09/2009 | 07/08/2009 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND | 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelsons syndrome MedDRA version: 9.1;Level: LLT;Classification code 10051747 | Product Name: PASIREOTIDE Product Code: SOM230 INN or Proposed INN: PASIREOTIDE Product Name: PASIREOTIDE Product Code: SOM230 INN or Proposed INN: PASIREOTIDE Product Name: PASIREOTIDE Product Code: SOM230 INN or Proposed INN: PASIREOTIDE | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 70 | France;Spain;Germany;Italy | |||
| 2 | EUCTR2008-007348-32-DE (EUCTR) | 12/08/2009 | 30/06/2009 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson's syndrome MedDRA version: 14.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | United States;Spain;Russian Federation;Colombia;Italy;France;Mexico;Canada;Argentina;Brazil;Australia;South Africa;Germany | ||
| 3 | EUCTR2008-007348-32-FR (EUCTR) | 06/05/2009 | 05/06/2009 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson’s syndrome MedDRA version: 9.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor | Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | France;Spain;Germany;Italy | ||
| 4 | EUCTR2006-007036-95-DE (EUCTR) | 02/07/2008 | 23/01/2009 | Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study | Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study | Prolactinoma MedDRA version: 9.1;Level: LLT;Classification code 10036832;Term: Prolactinoma | Product Code: SOM230 INN or Proposed INN: Pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide | Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie | NULL | Not Recruiting | Female: yes Male: yes | Germany |